SODIUM POLYSTYRENE SULFONATE Suspension, USP

Size: px
Start display at page:

Download "SODIUM POLYSTYRENE SULFONATE Suspension, USP"

Transcription

1 SODIUM POLYSTYRENE SULFONATE Suspension, USP DESCRIPTION Sodium Polystyrene Sulfonate Suspension, USP can be administered orally or in an enema. It is a cherryflavored suspension containing 15 grams of cation-exchange resin (Sodium Polystyrene Sulfonate USP). In addition sodium polystyrene sulfonate suspension contains the following inactive ingredients: citric acid, artificial flavor (cherry), magnesium aluminum silicate, methylparaben, propylene glycol, propylparaben, sucralose, and purified water. Sodium polystyrene sulfonate is a benzene, diethenyl-, polymer with ethenylbenzene, sulfonated, sodium salt and has the following structural formula: The sodium content of the suspension is 1575 mg (68.5 meq) per 60 ml which is equivalent to 1500 mg on the anhydrous basis. It is an amber, smooth suspension with an in-vitro exchange capacity of approximately 3.1 meq (in-vivo approximately 1 meq) of potassium per 4 ml (1 gram) of suspension. It can be administered orally or in an enema. CLINICAL PHARMACOLOGY As the resin passes along the intestine or is retained in the colon after administration by enema, the sodium ions are partially released and are replaced by potassium ions. For the most part, this action occurs in the large intestine, which excretes potassium ions to a greater degree than does the small intestine. The efficiency of this process is limited and unpredictably variable. It commonly approximates the order of 33%, but the range is so large that definitive indices of electrolyte balance must be clearly monitored. Metabolic data are unavailable.

2 INDICATIONS AND USAGE Sodium Polystyrene Sulfonate Suspension, USP is indicated for the treatment of hyperkalemia. CONTRAINDICATIONS Sodium Polystyrene Sulfonate Suspension, USP is contraindicated in the following conditions: patients with hypokalemia, patients with a history of hypersensitivity to polystyrene sulfonate resins, obstructive bowel disease, oral or rectal administration in neonates (see PRECAUTIONS). WARNINGS Intestinal Necrosis Cases of intestinal necrosis, which may be fatal, and other serious gastrointestinal adverse events (bleeding, ischemic colitis, perforation) have been reported in association with sodium polystyrene sulfonate use. The majority of these cases reported the concomitant use of sorbitol. Risk factors for gastrointestinal adverse events were present in many of the cases including prematurity, history of intestinal disease or surgery, hypovolemia, and renal insufficiency and failure. Concomitant administration of additional sorbitol is not recommended (see PRECAUTIONS: Drug Interactions). Use only in patients who have normal bowel function. Avoid use in patients who have not had a bowel movement post-surgery. Avoid use in patients who are at risk for developing constipation or impaction (including those with history of impaction, chronic constipation, inflammatory bowel disease, ischemic colitis, vascular intestinal atherosclerosis, previous bowel resection, or bowel obstruction). Discontinue use in patients who develop constipation. Alternative Therapy in Severe Hyperkalemia Since the effective lowering of serum potassium with sodium polystyrene sulfonate may take hours to days, treatment with this drug alone may be insufficient to rapidly correct severe hyperkalemia associated with states of rapid tissue breakdown (e.g., burns and renal failure) or hyperkalemia so marked as to constitute a medical emergency. Therefore, other definitive measures, including dialysis, should always be considered and may be imperative. Hypokalemia Serious potassium deficiency can occur from sodium polystyrene sulfonate therapy. The effect must be carefully controlled by frequent serum potassium determinations within each 24 hour period. Since intracellular potassium deficiency is not always reflected by serum potassium levels, the level at which treatment with sodium polystyrene sulfonate should be discontinued must be determined individually for each patient. Important aids in making this determination are the patient s clinical condition and electrocardiogram. Early clinical signs of severe hypokalemia include a pattern of irritable confusion and delayed thought processes.

3 Electrocardiographically, severe hypokalemia is often associated with a lengthened Q-T interval, widening, flattening, or inversion of the T wave, and prominent U waves. Also, cardiac arrhythmias may occur, such as premature atrial, nodal, and ventricular contractions, and supraventricular and ventricular tachycardias. The toxic effects of digitalis are likely to be exaggerated. Marked hypokalemia can also be manifested by severe muscle weakness, at times extending into frank paralysis. Electrolyte Disturbances Like all cation-exchange resins, sodium polystyrene sulfonate is not totally selective (for potassium) in its actions, and small amounts of other cations such as magnesium and calcium can also be lost during treatment. Accordingly, patients receiving sodium polystyrene sulfonate should be monitored for all applicable electrolyte disturbances. Systemic Alkalosis Systemic alkalosis has been reported after cation-exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with sodium polystyrene sulfonate. One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given sodium polystyrene sulfonate with magnesium hydroxide as a laxative (see PRECAUTIONS: Drug Interactions). PRECAUTIONS Caution is advised when sodium polystyrene sulfonate is administered to patients who cannot tolerate even a small increase in sodium loads (i.e., severe congestive heart failure, severe hypertension, or marked edema). In such instances compensatory restriction of sodium intake from other sources may be indicated. Precautions should be taken to ensure the use of adequate volumes of sodium-free cleansing enemas after rectal administration. In the event of clinically significant constipation, treatment with sodium polystyrene sulfonate should be discontinued until normal bowel motion is resumed (see WARNINGS: Intestinal Necrosis). Drug Interactions Antacids: The simultaneous oral administration of sodium polystyrene sulfonate with nonabsorbable cation-donating antacids and laxatives may reduce the resin s potassium exchange capability. Nonabsorbable cation-donating antacids and laxatives: Systemic alkalosis has been reported after cation exchange resins were administered orally in combination with nonabsorbable cation-donating antacids and laxatives such as magnesium hydroxide and aluminum carbonate. Magnesium hydroxide should not be administered with sodium polystyrene sulfonate. One case of grand mal seizure has been reported in a patient with chronic hypocalcemia of renal failure who was given sodium polystyrene sulfonate with magnesium hydroxide as a laxative.

4 Intestinal obstruction due to concretions of aluminum hydroxide when used in combination with sodium polystyrene sulfonate has been reported. Digitalis: The toxic effects of digitalis on the heart, especially various ventricular arrhythmias and A-V nodal dissociation, are likely to be exaggerated by hypokalemia, even in the face of serum digoxin concentrations in the normal range (see WARNINGS). Sorbitol: Concomitant use of sorbitol with sodium polystyrene sulfonate has been implicated in cases of intestinal necrosis, which may be fatal (see WARNINGS). Lithium: Sodium polystyrene sulfonate may decrease absorption of lithium. Thyroxine: Sodium polystyrene sulfonate may decrease absorption of thyroxine. Carcinogenesis, Mutagenesis, Impairment of Fertility Studies have not been performed. Pregnancy Animal reproduction studies have not been conducted with sodium polystyrene sulfonate. It is also not known whether sodium polystyrene sulfonate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium polystyrene sulfonate should be given to a pregnant woman only if clearly needed. Nursing Mothers It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sodium polystyrene sulfonate is administered to a nursing woman. Pediatric Use The effectiveness of sodium polystyrene sulfonate in pediatric patients has not been established. The use of sodium polystyrene sulfonate is contraindicated in neonates and especially in premature infants. In children and neonates, particular care should be observed with rectal administration, as excessive dosage could result in impaction of the resin. Precautions should be taken to ensure the use of adequate volumes of sodium-free cleansing enemas after rectal administration. ADVERSE REACTIONS Sodium polystyrene sulfonate suspension may cause some degree of gastric irritation. Anorexia, nausea, vomiting, and constipation may occur especially if high doses are given. Also, hypokalemia, hypocalcemia, hypomagnesemia and significant sodium retention, and their related clinical manifestations, may occur (see WARNINGS). Occasionally diarrhea develops. Large doses in elderly individuals may cause fecal impaction (see PRECAUTIONS). Rare instances of intestinal necrosis have been reported. Intestinal obstruction due to concretions of aluminum hydroxide, when used in combination with sodium polystyrene sulfonate, has been reported.

5 The following events have been reported from worldwide post marketing experience: Fecal impaction following rectal administration, particularly in children; Gastrointestinal concretions (bezoars) following oral administration; Ischemic colitis, gastrointestinal tract ulceration or necrosis which could lead to intestinal perforation; and Rare cases of acute bronchitis and/or bronchopneumonia associated with inhalation of particles of polystyrene sulfonate. OVERDOSAGE Overdosage may result in electrolyte disturbances including hypokalemia, hypocalcemia, and hypomagnesemia. Biochemical disturbances resulting from overdosage may give rise to clinical signs and symptoms of hypokalemia, including: irritability, confusion, delayed thought processes, muscle weakness, hyporeflexia, which may progress to frank paralysis and/or apnea. Tetany may occur. Electrocardiographic changes may be consistent with hypokalemia or hypercalcemia; cardiac arrhythmias may occur. Appropriate measures should be taken to correct serum electrolytes (potassium, calcium, magnesium), and the resin should be removed from the alimentary tract by appropriate use of laxatives or enemas. DOSAGE AND ADMINISTRATION The average daily adult dose is 15 g (60 ml) to 60 g (240 ml) of suspension. This is best provided by administering 15 g (60 ml) of sodium polystyrene sulfonate suspension one to four times daily. Each 60 ml of sodium polystyrene sulfonate suspension contains 1575 mg (68.5 meq) per 60 ml which is equivalent to 1500 mg on the anhydrous basis of sodium. Since the in-vivo efficiency of sodiumpotassium exchange resins is approximately 33%, about one-third of the resin s actual sodium content is being delivered to the body. In smaller children and infants, lower doses should be employed by using as a guide a rate of 1 meq of potassium per gram of resin as the basis for calculation. Sodium polystyrene sulfonate suspension may be introduced into the stomach through a plastic tube and, if desired, given with a diet appropriate for a patient in renal failure. Sodium polystyrene sulfonate suspension may also be given, although with less effective results, as an enema consisting (for adults) of 30 g (120 ml) to 50 g (200 ml) every six hours. The enema should be retained as long as possible and followed by a cleansing enema. After an initial cleansing enema, a soft, large size (French 28) rubber tube is inserted into the rectum for a distance of about 20 cm, with the tip well into the sigmoid colon, and taped in place. The suspension is introduced at body temperature by gravity. The suspension is flushed with 50 or 100 ml of fluid, following which the tube is clamped and left in place. If back leakage occurs, the hips are elevated on pillows or a knee-chest position is taken temporarily. The suspension is kept in the sigmoid colon for several hours, if possible. Then, the colon is irrigated with a sodium-free cleansing enema at body temperature in order to remove the resin. Two quarts of flushing solution may be necessary. The

6 returns are drained constantly through a Y tube connection. While the use of sorbitol is not recommended, particular attention should be paid to this cleansing enema if sorbitol has been used. The intensity and duration of therapy depend upon the severity and resistance of hyperkalemia. Sodium polystyrene sulfonate suspension should not be heated for to do so may alter the exchange properties of the resin. HOW SUPPLIED Sodium Polystyrene Sulfonate Suspension, USP, 15 g per 60 ml Amber-colored, cherry-flavored suspension NDC : Unit dose bottles filled to deliver 60 ml. NDC : Unit of use enema bottles filled to contain 120 ml (for use in delivering the suspension rectally through appropriate tubing). NDC : Unit of use enema bottles filled to contain 200 ml (for use in delivering the suspension rectally through appropriate tubing). NDC : Bottles of 500 ml. Dispense in a tight container, as defined in the USP/NF. If repackaging into other containers, store in refrigerator and use within 14 days of packaging. SHAKE WELL BEFORE USING. Store at 25 C (77 F); excursions permitted to 15 to 30 C (59 to 86 F). [See USP Controlled Room Temperature]. Roxane Laboratories, Inc. Columbus, Ohio /02 Revised June 2013 RLI, 2013

PRODUCT INFORMATION RESONIUM A. Na m

PRODUCT INFORMATION RESONIUM A. Na m PRODUCT INFORMATION RESONIUM A NAME OF THE MEDICINE Non-proprietary Name Sodium polystyrene sulfonate Chemical Structure CH - 2 CH SO 3 Na + n CAS Number 28210-41-5 [9003-59-2] CH 2 CH SO - 3 m DESCRIPTION

More information

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate)

Draft Labeling Package Insert Not Actual Size. BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) Draft Labeling Package Insert Not Actual Size BRAINTREE LABORATORIES, INC. PhosLo Capsules (Calcium Acetate) DESCRIPTION: Full Size: Each opaque capsule with a white cap and white body is spin printed

More information

ADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6.

ADVERSE REACTIONS The most common (>10%) adverse reactions are hypercalcemia, nausea, and diarrhea. (6. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PHOSLYRA safely and effectively. See full prescribing information for PHOSLYRA. PHOSLYRA (calcium

More information

SUCRALFATE TABLETS, USP

SUCRALFATE TABLETS, USP 1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:

More information

Document 3 Summary of Data and Guidance for Medical Professionals

Document 3 Summary of Data and Guidance for Medical Professionals Document 3 Summary of Data and Guidance for Medical Professionals Anvirzel Anvirzel is a novel antitumor compound extracted from the plant Nerium oleander, which belongs to the family Apocynaceae. Anvirzel

More information

SUCRALFATE TABLETS, USP

SUCRALFATE TABLETS, USP 1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:

More information

[Al(OH) 3. ] x [H 2. O]y

[Al(OH) 3. ] x [H 2. O]y CARAFATE (sucralfate) ral Suspension DESCRIPTIN CARAFATE ral Suspension contains sucralfate and sucralfate is an α-d-glucopyranoside, β-dfructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex.

More information

K-TAB (potassium chloride extended-release tablets, USP)

K-TAB (potassium chloride extended-release tablets, USP) K-TAB (potassium chloride extended-release tablets, USP) DESCRIPTION K-TAB (potassium chloride extended-release tablets) is a solid oral dosage form of potassium chloride containing 8 meq, 10 meq and 20

More information

PRODUCT INFORMATION UROCIT -K. Wax matrix tablets

PRODUCT INFORMATION UROCIT -K. Wax matrix tablets PRODUCT INFORMATION UROCIT -K Wax matrix tablets NAME OF DRUG Potassium Citrate CAS number- 6100-05-6 The empirical formula of potassium citrate is K 3 C 6 H 5 0 7.H 2 O, and its structural formula is:

More information

MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350)

MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) MOVICOL Junior Chocolate Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Chocolate Flavour Product Description: Each sachet of MOVICOL Junior Chocolate contains: Macrogol 3350

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Magnesium Trisilicate Mixture B.P. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Magnesium Trisilicate B.P. 250 mg/5 ml Light Magnesium

More information

PACKAGE INSERT CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher mosmol/ml 680 mosmol/l Ca meq/ml ph

PACKAGE INSERT CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher mosmol/ml 680 mosmol/l Ca meq/ml ph CALCIUM GLUCONATE INJECTION, USP 10% Electrolyte Replenisher 0.68 mosmol/ml 680 mosmol/l Ca ++ 0.465 meq/ml ph 6.0 8.2 DESCRIPTION Calcium Gluconate Injection, USP is a sterile, nonpyrogenic supersaturated

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm Junior, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of contains the following active

More information

PRODUCT MONOGRAPH UROCIT -K. (Potassium Citrate Extended-Release Tablets, USP)

PRODUCT MONOGRAPH UROCIT -K. (Potassium Citrate Extended-Release Tablets, USP) PRODUCT MONOGRAPH UROCIT -K (Potassium Citrate Extended-Release Tablets, USP) Renal Stone treatment in patients with hypocitraturia or uric acid lithiasis Mission Pharmacal Company Date of Revision: 10999

More information

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350)

MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) MOVICOL Liquid Orange Flavour Concentrate for Oral Solution (macrogol 3350) NAME OF THE MEDICINE: MOVICOL Liquid Orange Flavour, Concentrate for Oral Solution. DESCRIPTION: A clear colourless solution.

More information

MOVICOL Junior Powder for Solution (macrogol 3350)

MOVICOL Junior Powder for Solution (macrogol 3350) MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride

More information

Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg

Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Rx only DESCRIPTION Leucovorin Calcium Tablets USP contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]

More information

Electrolyte Imbalance and Resuscitation. Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine

Electrolyte Imbalance and Resuscitation. Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine Electrolyte Imbalance and Resuscitation Dr. Mehmet Okumuş Sütçü Imam University Faculty of Medicine Department of Emergency Medicine Presentation plan Definition of the electrolyte disturbances Conditions

More information

MOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l

MOVICOL HALF PI December MOVICOL-Half. Powder for Solution (macrogol 3350) Potassium 5.4 mmol/l. Bicarbonate 17 mmol/l MOVICOL -Half Powder for Solution (macrogol 3350) Product Name: Product Description: MOVICOL-Half Each sachet of MOVICOL-Half contains: Macrogol 3350 6.563 g Sodium chloride 175.4 mg Sodium bicarbonate

More information

KEVEYIS (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958

KEVEYIS (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEVEYIS safely and effectively. See full prescribing information for KEVEYIS. KEVEYIS (dichlorphenamide)

More information

PRODUCT MONOGRAPH K-DUR. (Potassium Chloride) Sustained Release Tablets mg - 20 mmol (meq)

PRODUCT MONOGRAPH K-DUR. (Potassium Chloride) Sustained Release Tablets mg - 20 mmol (meq) PRODUCT MONOGRAPH K-DUR (Potassium Chloride) Sustained Release Tablets 1500 mg - 20 mmol (meq) Merck Canada Inc. 16750 route Transcanadienne Kirkland, Quebec H9H 4M7 DATE OF PREPARATION: March 2, 2011

More information

Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate.

Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate. NAME OF THE MEDICINE KLYX Enema Active ingredients per ml: Docusate sodium 1 mg/sorbitol solution (70%) (crystallising) 357 mg Structural formula: Docusate Sorbitol C20H37NaO7S MW: 444.56 CAS no: 577-11-7

More information

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant

More information

CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP)

CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) DESCRIPTION CORTISPORIN Cream (neomycin and polymyxin B sulfates and hydrocortisone acetate cream, USP) is a

More information

FIRST DOSE: Begin Step 1 at PM the evening before your procedure and proceed as shown below:

FIRST DOSE: Begin Step 1 at PM the evening before your procedure and proceed as shown below: FILL LINE Your procedure will be performed by Doctor: Address: Date of procedure: Arrive at: AM/PM Comments: On the day before your procedure What You CAN do: You may have a light breakfast or have clear

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients:

2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution contains the following active ingredients: SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Macrovic Junior powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Macrovic Junior powder for oral solution

More information

MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350)

MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) MOVICOL Lemon-Lime Flavour Powder for Solution (macrogol 3350) Product Name: MOVICOL Lemon-Lime Flavour Product Description: Each sachet of MOVICOL Lemon-Lime contains: Macrogol 3350 Sodium chloride Sodium

More information

Important Prescribing Information

Important Prescribing Information Important Prescribing Information Subject: Temporary importation of Potassium Chloride (KCl) Injection, Concentrate, 2 meq/ml to address drug shortage issues July 11, 2018 Dear Healthcare Professional,

More information

NORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container

NORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container NORMOSOL -R MULTIPLE ELECTROLYTES INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Flexible Plastic Container R x only DESCRIPTION Normosol-R is a sterile, nonpyrogenic isotonic

More information

DESCRIPTION Bethanechol chloride, USP, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine.

DESCRIPTION Bethanechol chloride, USP, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related to acetylcholine. BETHANECHOL CHLORIDE TABLETS, USP 5 mg, 10 mg, 25 mg and 50 mg Rx only DESCRIPTION Bethanechol chloride, USP, a cholinergic agent, is a synthetic ester which is structurally and pharmacologically related

More information

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP)

NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP) NEOSPORIN Ophthalmic Solution Sterile (neomycin and polymyxin B sulfates and gramicidin ophthalmic solution, USP) NEOSPORIN SOLUTION DESCRIPTION NEOSPORIN Ophthalmic Solution (neomycin and polymyxin B

More information

CONTRAINDICATIONS None (4)

CONTRAINDICATIONS None (4) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cystadane safely and effectively. See full prescribing information for Cystadane. Cystadane (betaine

More information

Package Insert. Constipeg

Package Insert. Constipeg Package Insert Constipeg Product Summary 1. Name of the medicinal product Constipeg sachets 2. Qualitative and quantitative composition Each 13.7 g sachet contains PEG polyethylene glycol (macrogol) USNF

More information

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

SUMMARY OF PRODUCT CHARACTERISTICS. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients: SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Lacrofarm, powder for oral solution, sachet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains the following active ingredients:

More information

Package Insert. D-Bright

Package Insert. D-Bright Package Insert D-Bright Product Summary 1. Name of the medicinal product D-Bright 2. Qualitative and quantitative composition Each ml contains Cholecalciferol (Vitamin D3) IP 400 IU in a flavoured syrupy

More information

Reference ID:

Reference ID: MEDICATION GUIDE CLENPIQ (CLEN-pik) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) oral solution Read and understand these Medication Guide instructions at least 2 days before your colonoscopy

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound

More information

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP

PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)

More information

PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker

PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker PACKAGE INSERT Pr PHENTOLAMINE MESYLATE INJECTION SANDOZ STANDARD 5 mg/ ml THERAPEUTIC CLASSIFICATION Alpha-adrenoreceptor Blocker ACTIONS AND CLINICAL PHARMACOLOGY Phentolamine produces an alpha-adrenergic

More information

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution.

SUMMARY OF THE PRODUCT CHARACTERISTICS. The content of electrolyte ions per sachet when made up to 125 ml of solution. SUMMARY OF THE PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Molaxole powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet contains following active substances Macrogol

More information

Basic Fluid and Electrolytes

Basic Fluid and Electrolytes Basic Fluid and Electrolytes Chapter 22 Basic Fluid and Electrolytes Introduction Infants and young children have a greater need for water and are more vulnerable to alterations in fluid and electrolyte

More information

3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container

3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container 3% Sorbitol Urologic Irrigating Solution in UROMATIC Plastic Container Description 3% Sorbitol Urologic Irrigating Solution is a sterile, nonpyrogenic, nonhemolytic, electrically nonconductive solution

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colecalciferol Meda 800 IU tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains colecalciferol (vitamin D 3 ) 800 IU

More information

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

2 QUALITATIVE AND QUANTITATIVE COMPOSITION SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Compound Macrogol 13.72 g powder for oral solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each sachet of Compound Macrogol 13.72 g

More information

PROSTIGMIN (neostigmine bromide)

PROSTIGMIN (neostigmine bromide) PROSTIGMIN (neostigmine bromide) TABLETS DESCRIPTION: Prostigmin (neostigmine bromide), an anticholinesterase agent, is available for oral administration in 15 mg tablets. Each tablet also contains gelatin,

More information

3 DOSAGE FORMS AND STRENGTHS

3 DOSAGE FORMS AND STRENGTHS PATADAY- olopatadine hydrochloride solution/ drops Alcon Laboratories, Inc. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PATADAY safely

More information

[Al(OH) 3. ] x [H 2. O]y

[Al(OH) 3. ] x [H 2. O]y CARAFATE Tablets (sucralfate) DESCRIPTIN CARAFATE Tablets contain sucralfate and sucralfate is an α-d-glucopyranoside, β-dfructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. R [Al(H) 3 ] x

More information

Calcium (Ca 2+ ) mg/dl

Calcium (Ca 2+ ) mg/dl Quick Guide to Laboratory Values Use this handy cheat-sheet to help you monitor laboratory values related to fluid and electrolyte status. Remember, normal values may vary according to techniques used

More information

Normal range of serum potassium is meq/l true hyperkalemia manifests clinically as : Clinical presentation : muscle and cardiac dysfunction

Normal range of serum potassium is meq/l true hyperkalemia manifests clinically as : Clinical presentation : muscle and cardiac dysfunction Potassium Disorders hyperkalemia Potassium is mainly an cation? What is the major physiological role of potassium in the body? What is the major regulatory system of serum potassium level? Which part of

More information

Major intra and extracellular ions Lec: 1

Major intra and extracellular ions Lec: 1 Major intra and extracellular ions Lec: 1 The body fluids are solutions of inorganic and organic solutes. The concentration balance of the various components is maintained in order for the cell and tissue

More information

Spironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.

Spironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism. SPIRONE Composition Each tablet contains Spironolactone 100 mg. Tablets Action Spironolactone is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors

More information

February 12, Re: 10% Calcium Chloride Injection, USP. Dear Healthcare Professional,

February 12, Re: 10% Calcium Chloride Injection, USP. Dear Healthcare Professional, Re: 10% Calcium Chloride Injection, USP Dear Healthcare Professional, In an effort to reduce medication errors and ensure patient safety, American Regent, Inc. is informing you of recent changes to the

More information

Diffuse active ulceration with mucosal necrosis, hemorrhage and pseudomembrane formation Pseudomembranous colitis, Infectious colitis, Acute ischemic

Diffuse active ulceration with mucosal necrosis, hemorrhage and pseudomembrane formation Pseudomembranous colitis, Infectious colitis, Acute ischemic Clinical summary A 34-year-old man with intracerebal and intraventricular hemorrhages Emergency operation Past history : IgA nephropathy chronic renal failure hemodialysis Profuse hematochezia developed

More information

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown

1/3/2008. Karen Burke Priscilla LeMone Elaine Mohn-Brown. Medical-Surgical Nursing Care, 2e Karen Burke, Priscilla LeMone, and Elaine Mohn-Brown Medical-Surgical Nursing Care Second Edition Karen Burke Priscilla LeMone Elaine Mohn-Brown Chapter 7 Caring for Clients with Altered Fluid, Electrolyte, or Acid-Base Balance Water Primary component of

More information

PHENOXYBENZAMINE HYDROCHLORIDE Capsules USP

PHENOXYBENZAMINE HYDROCHLORIDE Capsules USP PHENOXYBENZAMINE HYDROCHLORIDE Capsules USP Rx only DESCRIPTION Each Phenoxybenzamine Hydrochloride Capsule USP, with red cap and body, is imprinted with "54 036", and contains 10 mg of phenoxybenzamine

More information

GALLIUM CITRATE Ga 67 INJECTION

GALLIUM CITRATE Ga 67 INJECTION 511945-0903 September 2003 USA Bristol-Myers Squibb Medical Imaging 331 Treble Cove Road N. Billerica, MA 01862 USA GALLIUM CITRATE Ga 67 INJECTION FOR DIAGNOSTIC USE DESCRIPTION: Gallium Citrate Ga 67

More information

Understanding the Benefits and Risks

Understanding the Benefits and Risks LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus

More information

Potassium chloride injection (approximately diluted) is a parenteral fluid and electrolyte replenisher.

Potassium chloride injection (approximately diluted) is a parenteral fluid and electrolyte replenisher. POTASSIUM CHLORIDE- potassium chloride injection, solution, concentrate B. Braun Medical Inc. ---------- Potas s ium Chloride for Injection Concentrate USP (2 meq K + /ml) PHARMACY BULK PACKAGE NOT FOR

More information

PRESCRIBING INFORMATION K-10. (Potassium Chloride Oral Solution, 10% USP) POTASSIUM REPLACEMENT THERAPY

PRESCRIBING INFORMATION K-10. (Potassium Chloride Oral Solution, 10% USP) POTASSIUM REPLACEMENT THERAPY PRESCRIBING INFORMATION K-10 (Potassium Chloride Oral Solution, 10% USP) POTASSIUM REPLACEMENT THERAPY GlaxoSmithKline Inc Date of Revision: 7333 Mississauga Road North Aug 30, 2017 Mississauga, Ontario

More information

PRESCRIBING INFORMATION PRODUCT MONOGRAPH MANDELAMINE*

PRESCRIBING INFORMATION PRODUCT MONOGRAPH MANDELAMINE* PRESCRIBING INFORMATION PRODUCT MONOGRAPH MANDELAMINE* (Methenamine Mandelate Tablets USP) 500 mg Urinary Antibacterial DATE OF PREPARATION : 16-Aug-2005 8250 Décarie Blvd, suite 110 Montréal, QC Canada,

More information

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 )

SUMMARY OF PRODUCT CHARACTERISTICS. A 2.5ml single-dose bottle containing IU Cholecalciferol (equivalent to 625 micrograms vitamin D 3 ) SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 25 000 IU Oral Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION A 2.5ml single-dose bottle containing 25 000 IU Cholecalciferol

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Omnilax 10 g powder for oral solution, sachet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One sachet contains 10 g of macrogol 4000.

More information

DESCRIPTION: Each tablet for oral administration contains:

DESCRIPTION: Each tablet for oral administration contains: HYOSCYAMINE SULFATE 0.125 MG TABLETS Rx Only 1 2 3 4 DESCRIPTION: Each tablet for oral administration contains: I-Hyoscyamine sulfate... 0.125 mg Inactive ingredients include: green dye, lactose monohydrate,

More information

Normosol -R and 5% Dextrose Injection MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid

Normosol -R and 5% Dextrose Injection MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid Normosol -R and 5% Dextrose Injection MULTIPLE ELECTROLYTES AND 5% DEXTROSE INJECTION TYPE 1, USP For Replacing Acute Losses of Extracellular Fluid R x only Flexible Plastic Container DESCRIPTION Normosol-R

More information

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT

SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT "Carbellon" Tablets. 2. Qualitative and Quantitative Composition Active Constituents: Activated Charcoal Ph.Eur. Magnesium Hydroxide Ph.Eur.

More information

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).

Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.

More information

To report SUSPECTED ADVERSE REACTIONS, contact Avadel Pharmaceuticals (USA), Inc. at or FDA at FDA-1088 or

To report SUSPECTED ADVERSE REACTIONS, contact Avadel Pharmaceuticals (USA), Inc. at or FDA at FDA-1088 or HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KARBINAL ER safely and effectively. See full prescribing information for KARBINAL ER. Karbinal ER

More information

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION

DBL MAGNESIUM SULFATE CONCENTRATED INJECTION DBL MAGNESIUM SULFATE CONCENTRATED INJECTION NAME OF MEDICINE Magnesium Sulfate BP DESCRIPTION DBL Magnesium Sulfate Concentrated Injection is a clear, colourless, sterile solution. Each ampoule contains

More information

Instrumental determination of electrolytes in urine. Amal Alamri

Instrumental determination of electrolytes in urine. Amal Alamri Instrumental determination of electrolytes in urine Amal Alamri What is the Electrolytes? Electrolytes are positively and negatively chargedions, Found in Within body's cells extracellular fluids, including

More information

LOTRONEX and its authorized generic alosetron hydrochloride:

LOTRONEX and its authorized generic alosetron hydrochloride: LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The Prescribing Program for LOTRONEX TM Prescriber Education Slide Deck PROMETHEUS and the Link Design

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fultium 10 000 IU/ml Oral Drops, solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml oral solution contains: 10 000 IU Cholecalciferol

More information

AVIOMARIN 50 mg tablets

AVIOMARIN 50 mg tablets PACKAGE LEAFLET: INFORMATION FOR THE USER AVIOMARIN 50 mg tablets DIMENHYDRINATE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines

More information

Page 1 of 9 ISOLYTE M IN DEXTROSE - dextrose monohydrate, sodium acetate, potassium chloride, potassium phosphate, dibasic and sodium chloride injection, solution ---------- DESCRIPTION Each 100 ml of

More information

5/18/2017. Specific Electrolytes. Sodium. Sodium. Sodium. Sodium. Sodium

5/18/2017. Specific Electrolytes. Sodium. Sodium. Sodium. Sodium. Sodium Specific Electrolytes Hyponatremia Hypervolemic Replacing water (not electrolytes) after perspiration Freshwater near-drowning Syndrome of Inappropriate ADH Secretion (SIADH) Hypovolemic GI disease (decreased

More information

VELTASSA (patiromer) oral suspension

VELTASSA (patiromer) oral suspension VELTASSA (patiromer) oral suspension Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy

More information

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides

Package leaflet: Information for the user. SenEase 7.5 mg tablets. Sennosides Package leaflet: Information for the user SenEase 7.5 mg tablets Sennosides Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep

More information

Abiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC).

Abiraterone Acetate is an antiandrogen used in the treatment of Castration-Resistant Prostate Cancer(CRPC). For the use only of an Oncologist or a Hospital or a Laboratory ABIRATERONE ACETATE TABLETS Zabiteron-250 COMPOSITION Abiraterone Acetate Tablets 250mg Each uncoated tablets contains: Abiraterone Acetate

More information

Potassium Chloride in 0.9% Sodium Chloride Injection, USP in Plastic Container

Potassium Chloride in 0.9% Sodium Chloride Injection, USP in Plastic Container PRESCRIBING INFORMATION Potassium Chloride in 0.9% Sodium Chloride Injection, USP in Plastic Container VIAFLEX Container 20mmol/L Potassium Chloride in Sodium in 0.9% Chloride Injection 40mmol/L Potassium

More information

Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP

Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP Clodronate BE/H/PSUR/001/001 October 2011 Agreed CSP 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Intravenous use Treatment of hypercalcemia due to malignancy. Oral use Treatment of hypercalcemia

More information

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v.

PRESCRIBING INFORMATION WITH CONSUMER INFORMATION MYDRIACYL. tropicamide ophthalmic solution, USP. 0.5% and 1% w/v. PRESCRIBING INFORMATION WITH CONSUMER INFORMATION Pr MYDRIACYL tropicamide ophthalmic solution, USP 0.5% and 1% w/v Anticholinergic Alcon Canada Inc. 2665 Meadowpine Blvd. Mississauga, ON L5N 8C7 www.alcon.ca

More information

Colonoscopy. In the work-up of intestinal disorders For prevention and early recognition of colon cancer

Colonoscopy. In the work-up of intestinal disorders For prevention and early recognition of colon cancer The informed patient Colonoscopy In the work-up of intestinal disorders For prevention and early recognition of colon cancer How do I prepare for the examination? How is the examination performed? Colonoscopy

More information

Ca-C 1000 Calvive 1000 mg mg mg effervescent tablets

Ca-C 1000 Calvive 1000 mg mg mg effervescent tablets PACKAGE LEAFLET: INFORMATION FOR THE USER Ca-C 1000 Calvive 1000 mg + 327 mg + 1000 mg effervescent tablets CALCIUM LACTATE GLUCONATE, CALCIUM CARBONATE, ASCORBIC ACID (VITAMIN C) This leaflet is a copy

More information

Product Information. Powder for Oral Solution. DESCRIPTION: The ingredients of MOVIPREP ORANGE are contained in two separate sachets:

Product Information. Powder for Oral Solution. DESCRIPTION: The ingredients of MOVIPREP ORANGE are contained in two separate sachets: Product Information NAME OF THE MEDICINE: MOVIPREP ORANGE MOVIPREP ORANGE Powder for Oral Solution DESCRIPTION: The ingredients of MOVIPREP ORANGE are contained in two separate sachets: Sachet A: Macrogol

More information

Cordran Cream and Cordran Ointment Flurandrenolide, USP

Cordran Cream and Cordran Ointment Flurandrenolide, USP Cordran Cream and Cordran Ointment Flurandrenolide, USP DESCRIPTION Cordran (flurandrenolide, USP) is a potent corticosteroid intended for topical use. Flurandrenolide occurs as white to off-white, fluffy,

More information

8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension

8 USE IN SPECIFIC POPULATIONS Patients with Open-Angle Glaucoma or Ocular Hypertension 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Isopto Carpine safely and effectively. See full prescribing information for Isopto Carpine. Isopto

More information

50% Concentrated Injection

50% Concentrated Injection NAME OF THE MEDICINE. The molecular weight of the compound is 246.5 and the CAS registry number is 10034-99-8. The molecular formula is MgSO4, 7H2O. DESCRIPTION MAGNESIUM SULFATE HEPTAHYDRATE 50% CONCENTRATED

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER Perfan Injection 100 mg/20 ml Concentrate for Solution for Injection Active substance: enoximone Read all of this leaflet carefully before you

More information

PHARMACEUTICAL INFORMATION AZILSARTAN

PHARMACEUTICAL INFORMATION AZILSARTAN AZEARLY Tablets Each Tablet Contains Azilsartan 20/40/80 mg PHARMACEUTICAL INFORMATION AZILSARTAN Generic name: Azilsartan Chemical name: 2-Ethoxy-1-{[2'-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-

More information

The chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula:

The chemical name of acyclovir, USP is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6Hpurin-6-one; it has the following structural formula: Acyclovir Ointment, USP 5% DESCRIPTION Acyclovir, USP, is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment, USP 5% is a formulation for topical administration. Each gram

More information

Sodium Bicarbonate Injection, USP

Sodium Bicarbonate Injection, USP Sodium Bicarbonate Injection, USP FOR THE CORRECTION OF METABOLIC ACIDOSIS AND OTHER CONDITIONS REQUIRING SYSTEMIC ALKALINIZATION. Plastic Ansyr II Syringe R x only DESCRIPTION Sodium Bicarbonate Injection,

More information

45779C/Revised: April 2008 MANNITOL INJECTION, USP

45779C/Revised: April 2008 MANNITOL INJECTION, USP 45779C/Revised: April 2008 MANNITOL INJECTION, USP 25% For Intravenous Use and Urologic Irrigation DESCRIPTION: Mannitol is a 6-carbon sugar alcohol and has the following structure: C 6 H 14 O 6 182.17

More information

AquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1

AquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1 9073025 INJECTION AquaMEPHYTON (PHYTONADIONE) Aqueous Colloidal Solution of Vitamin K 1 WARNING - INTRAVENOUS AND INTRAMUSCULAR USE Severe reactions, including fatalities, have occurred during and immediately

More information

Should we be moving away from Kayexalate (Sodium Polystyrene Sulfonate)?

Should we be moving away from Kayexalate (Sodium Polystyrene Sulfonate)? Should we be moving away from Kayexalate (Sodium Polystyrene Sulfonate)? Shermaine Ngo, LMPS Pharmacy Resident Preceptor: Joanie Tulloch, Emergency Medicine Rotation May 2017 1 Learning Objectives Describe

More information

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY Rev. Mar. 2017 DESCRIPTION Each five-sided dye free MOTOFEN tablet contains: 1 mg of difenoxin (equivalent to 1.09 mg of difenoxin hydrochloride) and 0.025 mg of atropine sulfate (equivalent to 0.01 mg

More information

LEUCOVORIN CALCIUM - leucovorin calciumâ tabletâ Barr Laboratories Inc LEUCOVORIN CALCIUM TABLETS USP Â Rx only

LEUCOVORIN CALCIUM - leucovorin calciumâ tabletâ Barr Laboratories Inc LEUCOVORIN CALCIUM TABLETS USP Â Rx only LEUCOVORIN CALCIUM - leucovorin calcium tablet Barr Laboratories Inc. ---------- LEUCOVORIN CALCIUM TABLETS USP Rx only DESCRIPTION Leucovorin calcium tablets USP contain either 5 mg or 25 mg leucovorin

More information

SUPPLEMENT TO FIRST REPORT

SUPPLEMENT TO FIRST REPORT SUPPLEMENT TO ManagedCare FIRST REPORT PRODUCT BULLETIN This supplement was funded and developed in part, by Relypsa, Inc. MAY 2016 Hyperkalemia, or high potassium, is a potentially lifethreatening condition

More information

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.

Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic

More information

0.45% Sodium Chloride Injection, USP

0.45% Sodium Chloride Injection, USP PRESCRIBING INFORMATION 0.45% Sodium Chloride Injection, USP IV Fluid and Electrolyte Replenisher Baxter Corporation Mississauga, Ontario L5N 0C2 Canada Date of Revision: November 22, 2013 Submission Control

More information

INTRAVENOUS SOLUTIONS WITH POTASSIUM CHLORIDE POTASSIUM CHLORIDE IN LACTATED RINGER S AND 5% DEXTROSE INJECTION, USP Flexible Plastic Container

INTRAVENOUS SOLUTIONS WITH POTASSIUM CHLORIDE POTASSIUM CHLORIDE IN LACTATED RINGER S AND 5% DEXTROSE INJECTION, USP Flexible Plastic Container INTRAVENOUS SOLUTIONS WITH POTASSIUM CHLORIDE POTASSIUM CHLORIDE IN LACTATED RINGER S AND 5% DEXTROSE INJECTION, USP Flexible Plastic Container R x only DESCRIPTION Intravenous solutions with potassium

More information